AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6531440
Drug: Apomorphine HCl
RxNorm normalized name: apomorphine HCl
DrugBank: Apomorphine (DB00714)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apomorphine HCl (0.25, 0.5 or 0.75 mg sc)
Trial: 6531440
Drug: Benztropine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine (2 mg iv)
Trial: 31842106
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy twice a week (P2 group)
Trial: 31842106
Drug: Supervised physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised physical therapy once a week (P1 group)
Trial: 28447362
Drug: 595-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595-nm pulsed dye laser (PDL) treatment (fluence 8 J/cm3, pulse duration 10 ms, spot size 7 mm, 2 sessions every 2 weeks)
Trial: 28447362
Drug: 595-nm pulsed
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 595-nm pulsed dye laser (PDL) treatment
Trial: 23561694
Drug: Flurbiprofen 8.75
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75 mg microgranules
Trial: 21168109
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese acupuncture (TCA) weekly for 5 weeks
Trial: 21168109
Drug: Attention only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention only (practitioner present and participant supine) weekly for 5 weeks
Trial: 17928991
Drug: Urate oxidase
RxNorm normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Urate oxidase (1.5 mg)
Trial: 15110879
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy followed by myeloablative chemotherapy and autologous stem-cell rescue
Trial: 9206638
Drug: Topical decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim from the day before surgery until the 7th postoperative day
Trial: 9206638
Drug: Topical decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decontamination with polymyxin B, tobramycin, vancomycin and amphotericin B, and perioperative i.v. prophylaxis with cefotaxim
Trial: 7959618
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH), 0.1 IU/kg/day 6 days/week for 3 years (Group A)
Trial: 7959618
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and gonadotropin-releasing hormone agonist for the first 2 years (Group B)
Trial: 3318430
Drug: Nabumetone 1,000
RxNorm normalized name: nabumetone 1,000 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1,000 mg given at bedtime
Trial: 3318430
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg given twice daily
Trial: 31396625
Drug: EPA +
RxNorm normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPA + DHA supplementation, mean dosage 1983 ± 1297 mg/d, duration 13.6 ± 6.0 weeks
Trial: 24931587
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg twice daily)
Trial: 17037893
Drug: G Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G Bond (GC)
Trial: 15287927
Drug: Nateglinide monotherapy
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide monotherapy (120 mg before meals) in group 1 (diet alone or low-dose sulfonylureas)
Trial: 15287927
Drug: Nateglinide as
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide as add-on therapy (120 mg before meals) in group 2 (steady dose of metformin)
Trial: 8795327
Drug: Diclofenac suppositories
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppositories
Trial: 1505903
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (4 IU daily)
Trial: 6571404
Drug: Muscle discrimination
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle discrimination training during a headache treatment program that included standard behavioral procedures.
Trial: 30690638
Drug: Potent D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potent D2 antagonists
Trial: 30690638
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not taking potent D2 antagonists)
Trial: 20638231
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser treatment (EVL) using EVLT system
Trial: 15661480
Drug: 200 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g/d of avocado (30.6 g of fat)
Trial: 11836287
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg, twice a day)
Trial: 10452407
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg/d in a multivitamin syrup)
Trial: 106747
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray 50 microgram q.i.d.
Trial: 30344071
Drug: Individual voice
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual voice therapy
Trial: 15963687
Drug: Group voice
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group voice therapy
Trial: 31237119
Drug: Fenofibrate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (250 mg/d)
Trial: 25688781
Drug: Eliglustat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eliglustat (50 or 100 mg twice daily)
Trial: 21249415
Drug: Azithromycin (AZM)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (AZM) given once daily for 3 days
Trial: 21249415
Drug: Cefcapene-pivoxyl (CFPN-PI)
RxNorm normalized name: sulbactam pivoxyl
DrugBank: Sulbactam pivoxil (DB15761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefcapene-pivoxyl (CFPN-PI) divided into three daily doses for 5 days
Trial: 15301653
Drug: Monthly CBASP
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly CBASP
Trial: 11702804
Drug: Priming dose
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Priming dose of alcohol (0.55 g/kg)
Trial: 9627768
Drug: Triamterene/HCTZ (25/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamterene/HCTZ (25/12.5 mg)
Trial: 7837013
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin A treatment to the ipsilateral antagonist medial rectus
Trial: 3257843
Drug: Oral 25-hydroxyvitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25-hydroxyvitamin D 50 micrograms/day
Trial: 3257843
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral 25-hydroxyvitamin D
Trial: 6990761
Drug: Oral ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ritodrine
Trial: 27571777
Drug: Coaching intervention
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coaching intervention (leaflets and three monthly coaching sessions)
Trial: 25503598
Drug: 8% Capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% Capsaicin Patch (Qutenza)
Trial: 19248046
Drug: Vatalanib 1000
RxNorm normalized name: Vatalanib
DrugBank: Vatalanib (DB04879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vatalanib 1000 mg twice-a-day with imatinib (400 mg/day for stratum A, 500 mg twice-a-day for stratum B) and hydroxyurea (500 mg twice daily)
Trial: 17443208
Drug: Amphetamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (5 mg initially, then 10 mg for 10 subsequent doses with 3- or 4-day separations)
Trial: 8851875
Drug: Bismuth citrate/amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth citrate/amoxicillin combination therapy (BIAM tablet; 250 mg amoxicillin base and 120 mg bismuth)
Trial: 8851875
Drug: Bismuth citrate
RxNorm normalized name: Bismuth citrate
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth citrate monotherapy (BI tablet; 120 mg bismuth)
Trial: 8851875
Drug: Bismuth citrate/amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth citrate/amoxicillin combination therapy (BIAM)
Trial: 8851875
Drug: Bismuth citrate
RxNorm normalized name: Bismuth citrate
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth citrate monotherapy (BI)
Trial: 1294976
Drug: Cefamandole 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 1.5 g given one hour before surgery, repeated twice eight hourly, and throughout the operation if it lasted more than three hours
Trial: 1294976
Drug: Cefamandole 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole 1.5 g
Trial: 6202437
Drug: Prophylactic antiarrhythmic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antiarrhythmic therapy assigned to group 2 (53 patients).
Trial: 28240967
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg and Placebo
Trial: 15521668
Drug: Transcutaneous and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous and intranasal electric stimulation of nasal muscles only (Group 1)
Trial: 15521668
Drug: Surface and
RxNorm normalized name: BENZALKONIUM CHLORIDE 1.3 mg in 1 mL TOPICAL LIQUID [Micro Guard 24 HOUR Surface and Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surface and intranasal EMG biofeedback assisted specific strategies for nasal muscle education, home exercises and electric stimulation (Group 3)
Trial: 8449203
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (n=28)
Trial: 3544935
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 mg/day) for 12 weeks
Trial: 28854728
Drug: Second dose
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second dose of kisspeptin-54 (9.6 nmol/kg) administered 10 hours after the first dose.
Trial: 28854728
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of kisspeptin-54 (9.6 nmol/kg) administered 36 hours prior to oocyte retrieval and followed by saline 10 hours later.
Trial: 21458989
Drug: Psycho-educational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational group intervention (two weekly 6-h sessions of psycho-education and eight weekly 2-h sessions of group psychotherapy)
Trial: 21458989
Drug: Patients using
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients using anti-depressive medication (both intervention and control groups)
Trial: 14964334
Drug: Pulsed radio
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radio frequency energy therapy (PRFE)
Trial: 14964334
Drug: PRFE placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRFE placebo treatment (sham device)
Trial: 11117242
Drug: Bicarbonate/lactate peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate/lactate peritoneal dialysis solution (Bic/Lac)
Trial: 11117242
Drug: Standard lactate-buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard lactate-buffered peritoneal dialysis solution (Lac)
Trial: 3111705
Drug: Oral etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral etidronate disodium, 20 mg/kg/day
Trial: 3111705
Drug: Oral etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral etidronate disodium
Trial: 29254887
Drug: AZD8931 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8931 (40 mg twice a day)
Trial: 28818560
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (mean ± SD of 10.46 ± 4.63 mg/24 h, n = 17)
Trial: 28818560
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (n = 17)
Trial: 21173686
Drug: Midline group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midline group (intra-articular injection of 20 ml normal saline)
Trial: 21173686
Drug: Lateral group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral group (intra-articular injection of 20 ml normal saline)
Trial: 10977118
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus bupivacaine (Group A)
Trial: 10977118
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (Group B)
Trial: 2362952
Drug: Sulpiride 800
RxNorm normalized name: (±)-sulpiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 800 mg
Trial: 2362952
Drug: Sulpiride 1200
RxNorm normalized name: (±)-sulpiride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride 1200 mg
Trial: 20457702
Drug: Hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal treatment
Trial: 31418851
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy in Down syndrome
Trial: 31418851
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy in Down syndrome
Trial: 28887113
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg TCZ
Trial: 28887113
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg TCZ
Trial: 12849880
Drug: Both antiepileptic
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antiepileptic drugs
Trial: 9226732
Drug: 2 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/70 kg butorphanol, IV, in ice-cold water (2 degrees C)
Trial: 9226732
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg morphine, IV, in ice-cold water (2 degrees C)
Trial: 9226732
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg morphine, IV, in warm water (37 degrees C)
Trial: 9226732
Drug: 2 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/70 kg butorphanol, IV, in warm water (37 degrees C)
Trial: 11532487
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (control)
Trial: 22873117
Drug: l-NAME (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NAME (NO synthase inhibitor)
Trial: 16859516
Drug: Operant Behavioural
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Operant Behavioural Treatment (OBT)
Trial: 25031289
Drug: Gentamicin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 240 mg intramuscularly plus Azithromycin 2 g orally
Trial: 25031289
Drug: Gemifloxacin 320
RxNorm normalized name: gemifloxacin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 320 mg orally plus Azithromycin 2 g orally
Trial: 8678278
Drug: Alcuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.25 mg/kg with thiopentone 7 mg/kg i.v. (Group A)
Trial: 8678278
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg/kg with thiopentone 7 mg/kg i.v. (Group C)
Trial: 8678278
Drug: Alcuronium 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.25 mg/kg with propofol TIVA (Group B)
Trial: 8678278
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg/kg with propofol TIVA (Group D)
Trial: 8678278
Drug: Atracurium 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.5 mg/kg with thiopentone (Group E)
Trial: 8678278
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1% 3 mg/kg given at the beginning of recovery phase
Trial: 1359745
Drug: Zileuton 800
RxNorm normalized name: Zileuton
DrugBank: Zileuton (DB00744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zileuton 800 mg b.i.d.
Trial: 2870809
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine 1% applied twice daily for 28 days
Trial: 29336265
Drug: Topical Plantavera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Plantavera gel
Trial: 29336265
Drug: Topical Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Placebo gel
Trial: 24655487
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish (salmon) providing 274 mg EPA + 671 mg DHA per day
Trial: 24655487
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement providing 396 mg EPA + 250 mg DHA per day
Trial: 8598549
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplement
Trial: 20451454
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (18 g/m²)
Trial: 20451454
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (2 g/m²)
Trial: 12586512
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 'Fast' formulation (12 h)
Trial: 12586512
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg 'Slow' formulation (24 h)
Trial: 12586512
Drug: 2x15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x15 mg immediate release tablets (12 h interval)
Trial: 10669909
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of rifampicin and isoniazid
Trial: 10669909
Drug: Separate formulations
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulations of rifampicin and isoniazid
Trial: 8915147
Drug: Combination patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination patch testing (two different sets of five patches each containing combinations of three or four allergens per patch)
Trial: 8915147
Drug: Conventional patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional patch testing (17 standard allergens applied individually)
Trial: 8915147
Drug: Combination patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination patch testing (combination patches 1 and 2)
Trial: 8915147
Drug: Conventional patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional patch testing
Trial: 8915147
Drug: Combination patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination patch testing
Trial: 1855691
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of cimetidine 200 mg and alginic acid 500 mg, taken one tablet four times daily (increased to two tablets four times daily if response was unsatisfactory after six weeks)
Trial: 1855691
Drug: Standard dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosage of cimetidine 400 mg four times daily
Trial: 1855691
Drug: Combination tablet
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination tablet of cimetidine 200 mg and alginic acid 500 mg
Trial: 29544551
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) - intensive, group, and independent methods
Trial: 25307535
Drug: Achieved LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achieved LDL target (< 2.0 mmol/L)
Trial: 18022000
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (NAC) 300 mg along with hydration (500 mL multielectrolyte fluid)
Trial: 18022000
Drug: Hydration (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration (500 mL multielectrolyte fluid) only